@article{94ddf213ccfd430f95cad8a690ec2aef,
title = "To the editors: Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England",
author = "Bastian Tugemann and Navid Manouchehri and Olaf Stuve",
note = "Funding Information: O.S. serves on the editorial boards of Therapeutic Advances in Neurological Disorders. has served on data monitoring committees for Genentech-Roche, Pfizer, Novartis, and TG Therapeutics without monetary compensation, has advised EMD Serono, Celgene, Genentech, Genzyme, TG Therapeutics, and VYNE, currently receives grant support from EMD Serono and Exalys, is a 2021 recipient of a Grant for Multiple Sclerosis Innovation (GMSI), Merck KGaA, and is funded by a Merit Review grant (federal award document number (FAIN) BX005664-01 from the United States (U.S.) Department of Veterans Affairs, Biomedical Laboratory Research and Development. ",
year = "2022",
month = mar,
doi = "10.1016/j.msard.2022.103541",
language = "English (US)",
volume = "59",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",
}